Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients

In a large real-world cohort of kidney transplant recipients with type 2 diabetes, those started on a GLP-1 receptor agonist after transplant had substantially lower risks of death, cardiovascular events, and major kidney events than those who were not.